Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics, Array Genomics to Co-Develop CGH Diagnostics

NEW YORK, March 13 (GenomeWeb News) - CombiMatrix Molecular Diagnostics, a subsidiary of Acacia Research's CombiMatrix group, said today that it has signed an agreement with Paris-based Array Genomics to co-develop and co-market a series of comparative genomic hybridization microarrays for diagnosing genetic anomalies associated with mental retardation.

 

CombiMatrix Molecular Diagnostics will manufacture the arrays in the US, and Array Genomics will distribute them in Europe.

 

The arrays are expected to begin generating revenue for both companies "within the next several weeks," CMDX said in a statement.

 

The array-based CGH tests will reduce the time associated with the analysis of chromosomal imbalances compared to conventional cytogenetic approaches while increasing the detection resolution, CMDX said.

 

Matt Watson, CEO of CMDX, said in a statement that the company will also offer molecular diagnostic testing services based on CGH and gene expression profiling at its Irvine, Calif.-based clinical laboratory, and that it will also file "a number" of its tests with the US Food and Drug Administration for approval to market them within the US as in vitro diagnostics.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.